Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2018 Publisher: Aventis Pharma Limited, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK Trading as: Sanofi, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK
Suprefact Injection.
| Pharmaceutical Form |
|---|
|
Injection. |
Suprefact Injection contains 1.00mg buserelin as buserelin acetate in 1ml aqueous solution.
1.00mg buserelin is equivalent to 1.05mg buserelin acetate.
Suprefact Injection also contains 10mg benzyl alcohol in 1ml aqueous solution.
For full list of excipients, see section 6.1.
| Active Ingredient |
|---|
|
Buserelin is a synthetic peptide. It is a superactive analogue of natural gonadotrophin releasing hormone (gonadorelin, LHRH or GNRH). After an initial stimulation of gonadotrophin release, it down-regulates the hypothalanic-pituitary-gonadal axis. |
| List of Excipients |
|---|
|
Sodium chloride |
Box of 1 × 5.5 ml multidose vial containing 1.05 mg buserelin acetate per 1ml, corresponding to 1.00mg buserelin per 1 ml.
Pack size: 2 individual cardboard boxes are wrapped together in a clear plastic outer.
Aventis Pharma Limited, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK
Trading as: Sanofi, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK
PL 04425/0268
16 June 2006
| Drug | Countries | |
|---|---|---|
| SUPREFACT | Austria, Brazil, Canada, Spain, Netherlands, Singapore, United Kingdom, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.